Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells

Blood

Volumn 113, Issue 19, 2009, Pages 4681-4689

  Mumprecht, Sabine ^a   Claus, Christina ^a   Schürch, Christian ^a   Pavelic, Viktor ^a   Matter, Matthias S ^a   Ochsenbein, Adrian F ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; GLYCOPROTEIN; LEUKEMIA ANTIGEN; BCR ABL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSURVEILLANCE; LYMPH NODE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; THYMUS; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DISEASE MODEL; FLOW CYTOMETRY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RETROVIRUS; TRANSGENIC MOUSE; TUMOR CELL CULTURE; WHOLE BODY RADIATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GLYCOPROTEINS; IMMUNIZATION; IMMUNOLOGIC MEMORY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RETROVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; WHOLE-BODY IRRADIATION;

EID: 66549117391     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-156471     Document Type: Article

References (50)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183. (Pubitemid 40314949)
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.
3. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998;101:2290-2296. (Pubitemid 28244113)
4. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587-3592. (Pubitemid 26129585)
5. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892-2900.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
7. Dong R, Cwynarski K, Entwistle A, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 2003;101:3560-3567. (Pubitemid 36857942)
8. Orsini E, Calabrese E, Maggio R, et al. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. Leuk Res. 2006;30:785-794. (Pubitemid 43816701)
9. Mohty M, Isnardon D, Vey N, et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlate with loss of CD34+/CD38- primitive haematopoietic progenitors. Br J Haematol. 2002;119:115-118. (Pubitemid 35176507)
10. Boissel N, Rousselot P, Raffoux E, et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia. 2004;18:1656-1661. (Pubitemid 39386344)
11. Eisendle K, Lang A, Eibl B, et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol. 2003;120:63-73. (Pubitemid 36056910)
12. Wang C, Al-Omar HM, Radvanyi L, et al. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha. Exp Hematol. 1999;27:1176-1184. (Pubitemid 29284325)
13. Mohty M, Jarrossay D, Lafage-Pochitaloff M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98:3750-3756.
14. Dietz AB, Bulur PA, Erickson MR, et al. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematother Stem Cell Res. 2000;9:95-101.
15. Westermann J, Kopp J, van Lessen A, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol. 2007;137:297-306. (Pubitemid 46650246)
16. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792. (Pubitemid 28525205)
17. Ehl S, Hombach J, Aichele P, et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med. 1998;187:763-774. (Pubitemid 28115192)
18. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature. 1989;342:559-561. (Pubitemid 20005822)
19. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138. (Pubitemid 124000640)
20. Persons DA, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood. 1997;90:1777-1786.
21. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood. 1994;83:43-50. (Pubitemid 24016514)
22. Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus: liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J Exp Med. 1986;164:1075-1092. (Pubitemid 16031607)
23. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood. 2006;108:3406-3413. (Pubitemid 44776880)
24. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92:3829-3840. (Pubitemid 28525209)
25. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
26. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006;7:1092-1100. (Pubitemid 44420654)
27. Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol. 1999;27:1519-1527. (Pubitemid 29458426)
28. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639-647. (Pubitemid 36278582)
29. Schimmer AD, Pedersen IM, Kitada S, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res. 2003;63:1242-1248. (Pubitemid 36348701)
30. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412. (Pubitemid 29227526)
31. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133-1142. (Pubitemid 27079975)
32. Wallet MA, Sen P, Tisch R. Immunoregulation of dendritic cells. Clin Med Res. 2005;3:166-175.
33. Moller GM, Frost V, Melo JV, Chantry A. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett. 2007;581:1329-1334. (Pubitemid 46463955)
34. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21:494-504. (Pubitemid 46306561)
35. Schulz U, Munker R, Ertl B, Holler E, Kolb HJ. Different types of human leukemias express the message for TNF-alpha and interleukin-10. Eur J Med Res. 2001;6:359-363.
36. Pawelec G, Schlotz E, Rehbein A. IFN-alpha regulates IL 10 production by CML cells in vitro. Cancer Immunol Immunother. 1999;48:430-434. (Pubitemid 29503442)
37. Coppo P, Dusanter-Fourt I, Millot G, et al. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene. 2003;22:4102-4110. (Pubitemid 36819650)
38. Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol. 2006;134:171-179. (Pubitemid 43893908)
39. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525-9535. (Pubitemid 41508023)
40. Onai N, Obata-Onai A, Schmid MA, Manz MG. Flt3 in regulation of type I interferon-producing cell and dendritic cell development. Ann N Y Acad Sci. 2007;1106:253-261. (Pubitemid 47443051)
41. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48-54. (Pubitemid 38524698)
42. Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006;6:379-386.
43. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001;411:1058-1064. (Pubitemid 32612331)
44. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175-1180. (Pubitemid 44527353)
45. Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood. 1998;91:3414-3422. (Pubitemid 28193894)
46. Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999;94:4233-4246.
47. Palmer E. Negative selection: clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003;3:383-391. (Pubitemid 37323198)
48. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24:571-606.
49. Goldschneider I, Cone RE. A central role for peripheral dendritic cells in the induction of acquired thymic tolerance. Trends Immunol. 2003;24:77-81. (Pubitemid 36120643)
50. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.